Shift From Adalimumab Originator to Biosimilars in Denmark

被引：58

作者：

Jensen, Thomas Bo ^{[1
]}

Kim, Seoyoung C. ^{[2
]}

Jimenez-Solem, Espen ^{[1
]}

Bartels, Dorthe ^{[3
]}

Christensen, Hanne Rolighed ^{[1
]}

Andersen, Jon Traerup ^{[1
]}

机构：

[1] Copenhagen Univ Hosp Bispebjerg, Dept Clin Pharmacol, Bispebjerg Bakke 23,Entrance 20C,2nd Floor, DK-2400 Copenhagen NV, Denmark

[2] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA

[3] Amgros, Copenhagen, Denmark

来源：

JAMA INTERNAL MEDICINE | 2020年 / 180卷 / 06期

关键词：

D O I：

10.1001/jamainternmed.2020.0338

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：902 / 903

页数：2

共 50 条

[31] Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis
Gisondi, Paolo
Geat, Davide
Armeni, Patrizio
Bellinato, Francesco
Maurelli, Martina
Girolomoni, Giampiero
EXPERT OPINION ON BIOLOGICAL THERAPY, 2022, 22 (12) : 1579 - 1584
[32] Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience
Rosembert, D.
Malaviya, A.
How, J.
Tomlison, J.
Toh, F.
Roe, M.
Nightingale, A.
Garcia-Sueiro, C.
Herbert, P.
Jadon, D.
Norris, P.
Thomas, J.
Magsino, J.
Negoescu, A.
Raine, T.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S438 - S439
[33] Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial
Nabi, Hafsah
Georgiadis, Stylianos
Loft, Anne Gitte
Hendricks, Oliver
Jensen, Dorte Vendelbo
Andersen, Marlene
Chrysidis, Stavros
Colic, Ada
Danebod, Kamilla
Hussein, Mohamad Redha
Kalisz, Maren Hogberget
Kristensen, Salome
Lomborg, Niels
Manilo, Natalia
Munk, Heidi Lausten
Pedersen, Jens Kristian
Raun, Johnny Lillelund
Mehnert, Frank
Krogh, Niels Steen
Hetland, Merete Lund
Glintborg, Bente
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (11) : 1400 - 1409
[34] Biosimilars and originator biologicals- equivalence in anemia and neutropenia?
Link, H.
Oncology Research and Treatment, 2015, 38 : 196 - 197
[35] Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis
Song, Seok Hyeon
Woo, Se Joon
OCULAR IMMUNOLOGY AND INFLAMMATION, 2024, 32 (08) : 1755 - 1759
[36] Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues
Blandizzi, Corrado
Meroni, Pier Luigi
Lapadula, Giovanni
CLINICAL THERAPEUTICS, 2017, 39 (05) : 1026 - 1039
[37] Effectiveness and safety of switching from originator to biosimilar adalimumab in patients with psoriasis
Nielsen, Valdemar Wendelboe
Lund, Tamara Theresia
Gniadecki, Robert
Olsen, Rasmus Huan
Nissen, Christoffer Valdemar
Schwensen, Jakob Ferlov Baselius
Thomsen, Simon Francis
DERMATOLOGIC THERAPY, 2020, 33 (06)
[38] Switching between biosimilars and originator in hidradenitis suppurativa: retrospective study on biosimilar failure after originator
Cannizzaro, Maria Vittoria
Maffei, Virginia
Shumak, Ruslana Gaeta
Lambiase, Sara
Pensa, Chiara
Botti, Elisabetta
Bianchi, Luca
EXPERIMENTAL DERMATOLOGY, 2022, 31 : 113 - 114
[39] Biosimilars of adalimumab: the upcoming challenge in IBD
Fiorino, Gionata
Gilardi, Daniela
Correale, Carmen
Furfaro, Federica
Roda, Giulia
Loy, Laura
Argollo, Marjorie
Allocca, Mariangela
Peyrin-Biroulet, Laurent
Danese, Silvio
EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (10) : 1023 - 1030
[40] Navigating adalimumab biosimilars: an expert opinion
Abitbol, Vered
Benkhalifa, Salim
Habauzit, Caroline
Marotte, Hubert
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (11)

← 1 2 3 4 5 →